Compare CBU & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | BLLN |
|---|---|---|
| Founded | 1866 | 2016 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1994 | N/A |
| Metric | CBU | BLLN |
|---|---|---|
| Price | $64.19 | $89.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $64.00 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 217.9K | 166.0K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 40.41 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $746,303,000.00 | N/A |
| Revenue This Year | $13.79 | $98.01 |
| Revenue Next Year | $8.51 | $36.76 |
| P/E Ratio | $21.70 | ★ N/A |
| Revenue Growth | ★ 14.44 | N/A |
| 52 Week Low | $49.44 | $80.00 |
| 52 Week High | $67.50 | $138.70 |
| Indicator | CBU | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 51.46 |
| Support Level | $59.61 | $85.14 |
| Resistance Level | $67.00 | $98.26 |
| Average True Range (ATR) | 1.68 | 6.14 |
| MACD | -0.13 | 0.94 |
| Stochastic Oscillator | 42.88 | 53.71 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.